New CDMO, ten23 health, joins the biopharma industry

ten23 health, a contract development and manufacturing organization (CDMO), has announced its launch. The Switzerland-based company will be supporting biotech start-ups and established pharma customers in developing safe injectable biopharmaceutical drugs for patients.

The CDMO is run by an experienced team, including CEO Prof. Dr Hanns-Christian Mahler, alongside senior leaders with a proven track record in pharma product design and development. ten23 health’s goal is provide holistic design and development services with its pharmaceutical and application capabilities consisting of a development roadmap, de-risking strategies and support in its execution.

The company is also launching with sustainability in mind—it says it will aim for a net zero emissions target from the start.

“… We will deliver services in an engrained, fair and sustainable manner, respecting the future of the planet and people’s health,” says Richard Relyea, partner at investment company 3i Group who is financing the CDMO, and a member of ten23 health’s board of directors. “With our investment in ten23 health, we aim to support the establishment of a uniquely differentiated partner to leading global biotech and pharmaceutical customers in the development, manufacturing and testing of complex and effective injectable biopharmaceutical drugs.”